BioAegis Therapeutics is lead by a team of seasoned pharmaceutical executives with extensive operational, scientific and financial experience in life sciences.

Susan L. Levinson, Ph.D.
Chief Executive Officer

Susan Levinson-aSusan Levinson is a co-founder and the CEO of BioAegis, with over 30 years of life sciences consulting and pharmaceutical experience spanning the entire value chain, from the lab bench to marketing.

Prior to BioAegis, Dr. Levinson was the President of The Strategic Choice, a management consulting firm she founded after a successful career in the pharmaceutical industry. Dr. Levinson held executive positions in Business Strategy and Marketing Planning for Novartis Pharmaceuticals, leading key initiatives, including the implementation of a global brand planning model and managing the US annual strategic and tactical planning process. Prior to this, Dr. Levinson was responsible for New Product Marketing for women’s health, osteoporosis and chronic wound markets for the U.S.

She began her career at Novartis as Director of Licensing for the former Ciba-Geigy organization, where she led licensing strategy and negotiations within the Bone, Inflammation, Pulmonary and Oncology therapeutic areas. She began her career in Research, where as a Principal Scientist, she managed drug discovery programs at Ortho Pharmaceutical.

Susan has a B.S in Biochemistry from University of Wisconsin and a Ph.D. in Biomedical Sciences from Mount Sinai School of Medicine.

Valerie Ceva, MBA
Chief Operating Officer

Valerie Ceva-aValerie Ceva is the Chief Operating Officer, bringing to BioAegis a record of accomplishments in life science business development, strategic consulting and global venture capital transactions.

Prior to BioAegis, Ms. Ceva focused on emerging technology, supporting venture capital firms with investment strategy development and implementation and early stage companies in business model development, venture capital acquisition and operational execution, as a management consulting partner at The Strategic Choice and VentureWorks, LLC. Ms. Ceva’s work included several long-term projects such as: creation of a vaccine/diagnostic company and the development and execution of a new strategy for a top tier Private Equity firm. Ms. Ceva was a VP at I-TRAX.COM, Inc., a disease management application service provider, during its expansion/commercialization stage and IPO.

Prior to this, Ms. Ceva held executive positions at Novartis in Business Strategy, US and Corporate Business Development, Managed Care Marketing and Sales, as well as Venture Manager at Accel Partners. Ms. Ceva spearheaded some of Novartis’ most critical capability improvement initiatives including a reorganization and turnaround for the generic division, developing the company’s first lifecycle management strategy, leading post-merger integration initiatives.

Ms. Ceva has an MBA from University of Chicago and a BS in Biology from Bucknell University.

Mark J. DiNubile, MD, FIDSA
Chief Medical Officer

Mark DiNubileMark J. DiNubile, MD FIDSA, has recently joined BioAegis Therapeutics as our Chief Medical Officer to propel us forward into late-stage clinical development. He brings to the table the rare combination of clinical and research expertise along with broad pharmaceutical industry experience, coupled with his long-standing dedication to elucidating the clinical utility of plasma gelsolin. Mark is a board-certified physician in Internal Medicine and the subspecialty of Infectious Diseases. He joins BioAegis after 16 years at Merck & Co., Inc. where he was primarily focused on the therapeutic areas of Infectious Diseases and Vaccines. He has extensively published on a diverse spectrum of medical and scientific topics.

Mark graduated from the University of Pennsylvania summa cum laude with distinction in his major field of study (Psychology). He then attended Yale University School of Medicine, followed by completion of internship and residency at the Hospital of the University of Pennsylvania. As a fellow at Harvard, he completed his clinical Infectious Diseases requirements at the Brigham & Women’s Hospital followed by Hematology research focusing on neutrophil motility and phagocytosis at the Massachusetts General Hospital. During this period, he worked in the laboratory of our founding scientist Dr. Thomas P. Stossel. For the ensuing 16 years, Mark cared for patients in the ambulatory and hospital setting; taught medical students, house officers and fellows; chaired the hospital Pharmacy and Therapeutics Committee; initiated an antibiotic-stewardship program; and pursued clinical investigation and basic research, largely related to host defense and immunosuppression.

Thomas Stossel, MD
Board Member, Gelsolin Discoverer, Chair – Scientific Advisory Board

Thomas Stossel-aThomas Stossel is the discoverer of gelsolin, inventor of BioAegis’ technology estate, and Professor of Medicine, Harvard Medical School; American Cancer Society Clinical Research Professor and Senior Physician, Brigham and Women’s Hospital. He is the holder of numerous patents and author of more than 300 papers, studies and reviews. He is also a member of The National Academy of Sciences, The American Academy of Arts and Sciences, and the National Academy of Medicine, currently the Editor-in-Chief of Current Opinion in Hematology and Past Editor of Journal of Clinical Investigation, Past President of the American Society of Hematology and the American Society of Clinical Investigation. Dr. Stossel is a member of the Board of Directors of Velico Corporation. He has been awarded honorary MD degrees from the Universities of Linköping (Sweden) and Geneva (Switzerland).

He is currently a visiting scholar at the American Enterprise Institute. He and his wife Kerry have established a 501(c)(3) non-profit corporation, Options for Children in Zambia and has an Honorary Physician Position at University Teaching Hospital, Lusaka, Zambia, where he is working with Zambian physicians to improve management of sickle cell disease.

Dr. Stossel was educated at Princeton University and Harvard Medical School, trained in internal medicine at the Massachusetts General Hospital and in hematology at Boston Children’s and Peter Bent Brigham Hospitals.

Steven Cordovano
Corporate Development and Communications

Steven Cordovano-aSteven Cordovano brings to BioAegis a sophisticated market perspective and broad investor network gained through years of investment experience as a highly successful fund manager.

He has worked in finance and portfolio management for 25 years. Prior to BioAegis, Mr. Cordovano was a Partner with Trivalent Partners, where he assisted emerging growth companies in developing financing and communication strategies. Steve has been an advisor to several large institutional funds. From 2005 until 2009, Mr. Cordovano was the General Partner of HealthCare 250, L.P., a fund that invested solely in small to mid-cap health care companies.

From 1994 to 2005, he was a general partner in Gulfstream Partners, L.P., a long/short hedge fund that invested in multiple-sectors of the U.S. equity markets for individuals and pension funds. The fund was ranked by Financial World Magazine as the #1 performing hedge fund over three years, from 1994 to 1996. Through 15 years of management, Mr. Cordovano achieved overall average annual returns of 15%, exceeding the market throughout that same period. Mr. Cordovano began his financial services career in the Capital Markets division of Shearson Lehman Brothers in 1984.

Mr. Cordovano attended the business school of Villanova University and received his B.A. from Manhattanville College.